"10.1371_journal.pone.0045703","none","2012-09-19T00:00:00Z","Stine Marit Moen; Elisabeth Gulowsen Celius; Leiv Sandvik; Magritt Brustad; Lars Nordsletten; Erik Fink Eriksen; Trygve Holmøy","Department of Neurology, Oslo University Hospital Ullevål, Oslo, Norway; Section of Epidemiology and Biostatistics, Oslo University Hospital Ullevål, Oslo, Norway; Department of Community Medicine, University of Tromsø, Tromsø, Norway; Orthopedic Department, Oslo University Hospital Ullevål, Oslo, Norway; Department of Endocrinology, Oslo University Hospital, Oslo, Norway; Department of Neurology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway","Conceived and designed the experiments: SMM EGC LS MB LN TH. Performed the experiments: SMM. Analyzed the data: SMM LS MB. Contributed reagents/materials/analysis tools: MB LN EFE. Wrote the paper: SMM EGC TH. Revised the manuscript: SMM EGC LS MB LN EFE TH.","I have read the journal's policy and have the following conflicts. Stine Marit Moen has received funding for travel from Biogen Idec and European Charcot Foundation and has received research support from the South-Eastern Norway Regional Health Authority, Ullevål University Hospital, Biogen Idec, Odd Fellow Research Foundation for Multiple Sclerosis, the Endowment of K. and K.H. Hemsen, and the Endowment of Fritz and Ingrid Nilsen. Elisabeth Gulowsen Celius has received funding for travel and speaker honoraria from Sanofi-Aventis, Merck Serono, Biogen Idec, Bayer Schering Pharma, Teva, and Novartis; and receives research support from Biogen Idec and Novartis. Lars Nordsletten serves on scientific advisory boards for Novartis and DePuy Mitek, Inc.; has received funding for travel and speaker honoraria from Novartis, DePuy Mitek, Inc., Biomet Inc., Amgen, and Stryker, and serves on the editorial board of Acta Orthopaedica. Erik Fink Eriksen has served as a consultant for Eli Lilly and Company, Amgen, and Novartis; and serves on speakers’ bureaus for Novartis and Eli Lilly and Company. Trygve Holmøy has received funding for travel and speaker honoraria from Sanofi-Aventis, Merck Serono, Biogen Idec, Bayer Schering Pharma, and Novartis. This does not alter our adherence to all the PLoS ONE policies on sharing data and materials. The authors Magritt Brustad and Leiv Sandvik have declared that no competing interests exist.","2012","09","Stine Marit Moen","SMM",7,FALSE,6,1,3,3,TRUE,TRUE,FALSE,0,NA,FALSE
